Eli Lilly appoints Dr. Levi Garraway SVP

Dr. Levi Garraway has been appointed SVP of Global Development & Medical Affairs for the oncology business at Eli Lilly and Company.

Garraway, an associate professor in the Department of Medical Oncology at the Dana-Farber Cancer Institute, is a global leader in the analysis of cancer genomics and their resistance to therapies designed to target them. His appointment is effective Jan. 1.

"We are pleased and honored to have Dr. Garraway join us at Lilly," Sue Mahony, SVP at Lilly and president of Lilly Oncology. "He has made a tremendous impact in his career and is recognized around the world as a leader in oncology. We know he will provide keen insight and expertise — and will continue to advance Lilly's work in developing innovative new medicines to truly make life better for people with cancer around the world."

Garraway will succeed Dr. Richard Gaynor, who is retiring from Lilly.

"Richard is known for scientific rigor and deep expertise in drug development, coupled with a personal warmth and care for patients that is truly inspiring," Mahony said. "He is leaving a remarkable legacy at Lilly through his impact on the pipeline, people and patients."